Autism - Pipeline Review, H1 2014 @ This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

1. Autism - Pipeline Review, H1 2014
Autism - Pipeline Review, H1 2014
Summary
Global Markets Directs, Autism - Pipeline Review, H1 2014, provides an overview of the Autisms therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Autism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
- The report reviews key players involved in the therapeutics development for Autism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Autism products under development by companies and universities/research institutes based on information derived from company and
industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Autism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Autism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand
business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
table Of Contents 2
list Of Tables 8
list Of Figures 9
introduction 10
global Markets Direct Report Coverage 10
autism Overview 11
therapeutics Development 12
pipeline Products For Autism - Overview 12
pipeline Products For Autism - Comparative Analysis 13
autism - Therapeutics Under Development By Companies 14
autism - Therapeutics Under Investigation By Universities/institutes 17
autism - Pipeline Products Glance 19
late Stage Products 19
clinical Stage Products 20
early Stage Products 21
Autism - Pipeline Review, H1 2014

2. unknown Stage Products 22
autism - Products Under Development By Companies 23
autism - Products Under Investigation By Universities/institutes 25
autism - Companies Involved In Therapeutics Development 26
f. Hoffmann-la Roche Ltd. 26
dainippon Sumitomo Pharma Co., Ltd. 27
novartis Ag 28
merz Pharma Gmbh & Co. Kgaa 29
teva Pharmaceutical Industries Limited 30
avanir Pharmaceuticals, Inc. 31
snowdon Inc. 32
curemark, Llc 33
coronado Biosciences, Inc. 34
omeros Corporation 35
intra-cellular Therapies, Inc. 36
cellceutix Corporation 37
heptares Therapeutics Ltd. 38
otsuka Holdings Co., Ltd. 39
reviva Pharmaceuticals Inc. 40
naurex, Inc. 41
nectid, Inc. 42
mnemosyne Pharmaceuticals, Inc. 43
biocrea Gmbh 44
saniona Ab 45
confluence Pharmaceuticals Llc 46
autism - Therapeutics Assessment 47
assessment By Monotherapy Products 47
assessment By Combination Products 48
assessment By Target 49
assessment By Mechanism Of Action 52
assessment By Route Of Administration 55
assessment By Molecule Type 57
drug Profiles 59
cm-at - Drug Profile 59
product Description 59
mechanism Of Action 59
r&d Progress 59
lurasidone Hydrochloride - Drug Profile 60
product Description 60
mechanism Of Action 60
r&d Progress 60
aripiprazole - Drug Profile 62
product Description 62
mechanism Of Action 62
r&d Progress 62
cycloserine - Drug Profile 65
product Description 65
mechanism Of Action 65
r&d Progress 65
fluoxetine - Drug Profile 66
product Description 66
mechanism Of Action 66
r&d Progress 66
oxytocin - Drug Profile 68
product Description 68
mechanism Of Action 68
r&d Progress 68
oxytocin - Drug Profile 70
product Description 70
mechanism Of Action 70
r&d Progress 70
memantine Hydrochloride - Drug Profile 71
product Description 71
mechanism Of Action 71
r&d Progress 71
tso - Drug Profile 73
product Description 73
mechanism Of Action 73
Autism - Pipeline Review, H1 2014

3. r&d Progress 73
pioglitazone Hydrochloride - Drug Profile 75
product Description 75
mechanism Of Action 75
r&d Progress 75
oxytocin - Drug Profile 76
product Description 76
mechanism Of Action 76
r&d Progress 76
oxytocin - Drug Profile 78
product Description 78
mechanism Of Action 78
r&d Progress 78
(dextromethorphan Hydrobromide + Quinidine Sulfate) - Drug Profile 79
product Description 79
mechanism Of Action 79
r&d Progress 79
oxytocin - Drug Profile 81
product Description 81
mechanism Of Action 81
r&d Progress 81
oxytocin - Drug Profile 83
product Description 83
mechanism Of Action 83
r&d Progress 83
rg-7314 - Drug Profile 85
product Description 85
mechanism Of Action 85
r&d Progress 85
fluoxetine - Drug Profile 86
product Description 86
mechanism Of Action 86
r&d Progress 86
fluoxetine - Drug Profile 88
product Description 88
mechanism Of Action 88
r&d Progress 88
argipressin Tannate - Drug Profile 89
product Description 89
mechanism Of Action 89
r&d Progress 89
nu-211-01 + Nc-215-01 - Drug Profile 90
product Description 90
mechanism Of Action 90
r&d Progress 90
autologous Hematopoietic Stem Cells - Drug Profile 91
product Description 91
mechanism Of Action 91
r&d Progress 91
glatiramer Acetate - Drug Profile 93
product Description 93
mechanism Of Action 93
r&d Progress 93
iti-007 - Drug Profile 95
product Description 95
mechanism Of Action 95
r&d Progress 95
stem Cell Therapy For Central Nervous System Disorders - Drug Profile 97
product Description 97
mechanism Of Action 97
r&d Progress 97
km-391 - Drug Profile 98
product Description 98
mechanism Of Action 98
r&d Progress 98
program For Neurological Disorders - Drug Profile 100
product Description 100
mechanism Of Action 100
Autism - Pipeline Review, H1 2014

4. r&d Progress 100
stx-110 - Drug Profile 101
product Description 101
mechanism Of Action 101
r&d Progress 101
cn-2097 - Drug Profile 102
product Description 102
mechanism Of Action 102
r&d Progress 102
acamprosate Calcium - Drug Profile 103
product Description 103
mechanism Of Action 103
r&d Progress 103
small Molecules To Inhibit Pi3k For Autism And Fragile X Syndrome - Drug Profile 104
product Description 104
mechanism Of Action 104
r&d Progress 104
small Molecule Targeting Mglur5 - Drug Profile 105
product Description 105
mechanism Of Action 105
r&d Progress 105
nr-2a Modulators - Drug Profile 106
product Description 106
mechanism Of Action 106
r&d Progress 106
autism Program - Drug Profile 107
product Description 107
mechanism Of Action 107
r&d Progress 107
small Molecule Targeting Gpr63 For Autism - Drug Profile 108
product Description 108
mechanism Of Action 108
r&d Progress 108
nrx-20xx - Drug Profile 109
product Description 109
mechanism Of Action 109
r&d Progress 109
drug Targeting Gaba Alpha 4 Delta Receptor For Autism And Sleep Disorders - Drug Profile 110
product Description 110
mechanism Of Action 110
r&d Progress 110
small Molecules To Positively Modulate Gabaa Receptor For Epilepsy And Autism - Drug Profile 111
product Description 111
mechanism Of Action 111
r&d Progress 111
drugs For Autism - Drug Profile 112
product Description 112
mechanism Of Action 112
r&d Progress 112
rp-5063 - Drug Profile 113
product Description 113
mechanism Of Action 113
r&d Progress 113
nrt-34 - Drug Profile 114
product Description 114
mechanism Of Action 114
r&d Progress 114
carbetocin - Drug Profile 115
product Description 115
mechanism Of Action 115
r&d Progress 115
oxytocin - Drug Profile 116
product Description 116
mechanism Of Action 116
r&d Progress 116
autism - Recent Pipeline Updates 117
autism - Dormant Projects 139
autism - Discontinued Products 140
Autism - Pipeline Review, H1 2014

5. autism - Product Development Milestones 141
featured News & Press Releases 141
dec 12, 2013: Coronado Biosciences Announces Presentation Of Interim Data From Autism Study At Neuropsychopharmacology Meeting 141
nov 14, 2013: Stanford Drug Trial Seeks Participants With Autism Spectrum Disorder 141
nov 04, 2013: Curemark Begins Nda Submission For Cm-at Autism Treatment 142
sep 06, 2013: Avanir Pharmaceuticals Announces Settlement Of Nuedexta Patent Litigation With Wockhardt 142
sep 03, 2013: Avanir Pharmaceuticals Announces Settlement Of Nuedexta Patent Litigation With Actavis 143
aug 14, 2013: Avanir Pharmaceuticals Announces Settlement Of Nuedexta Patent Litigation With Sandoz 143
may 01, 2013: Seaside Therapeutics To Announce Results From Phase Iib Clinical Trial Of Arbaclofen In Autism Spectrum Disorder 144
apr 23, 2013: Curemark Announces Positive Pre-nda Meeting With Fda For New Drug Application For Cm-at For Autism 144
dec 03, 2012: Autism Speaks Awards $2m To Delsia For Partnership With Seaside Therapeutics To Develop Autism Treatments 145
nov 12, 2012: Coronado Biosciences Announces Initiation Of Investigator-initiated Study Evaluating Tso In Autism Spectrum Disorders 145
appendix 147
methodology 147
coverage 147
secondary Research 147
primary Research 147
expert Panel Validation 147
contact Us 148
disclaimer 148
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Autism - Pipeline Review, H1 2014